Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas.
In this study, we evaluated the miRNA profile in sixteen CRC tissues by Next-Generation-Sequencing and compared the circulating expression levels of 22 miRNAs among 45 CRC, 14 hyperplastic polyps, 11 advanced adenoma patients and 45 control subjects, by reverse transcription-quantitative PCR, to search for miRNAs which could be potential biomarkers. In total, nine of them represented 70% of total read counts (miR-10a-5p, miR-192-5p, miR-10b-5p, miR-22-3p, miR-26a-5p, miR-148a-3p, miR-181a-5p, miR-92a-3p and miR-143-5p). In silico analysis found eight candidates to mature miRNAs. With respect to circulating miRNA, we found ...
Source: Clinical Colorectal Cancer - July 20, 2019 Category: Cancer & Oncology Authors: Ardila HJ, Sanabria-Salas MC, Meneses X, Rios R, Huertas-Salgado A, Serrano ML Tags: Mol Clin Oncol Source Type: research

Roles of long non-coding RNAs in colorectal cancer tumorigenesis: A Review.
Abstract Long non-coding RNAs (lncRNAs) are newly identified potential biological and gene regulators. Similar to other cell-free circulating cancer-related nucleic acids, lncRNAs are released in the peripheral circulation of cancer patients and allow for non-invasive gene expression assessment. lncRNAs are considered to be promising biomarkers for cancer prognosis and diagnosis. Several lncRNAs have been found to regulate developmental processes in a number of biological disorders. Recent studies indicated that lncRNAs are associated with numerous diseases, most notably cancer, as they were found to be highly exp...
Source: Clinical Colorectal Cancer - July 11, 2019 Category: Cancer & Oncology Authors: Siddiqui H, Al-Ghafari A, Choudhry H, Doghaither HA Tags: Mol Clin Oncol Source Type: research

Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: A retrospective evaluation.
CONCLUSIONS: Sarcopenia was associated with worse CRC PFS and OS. These findings require prospective trials to validate this association. PMID: 31221274 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - June 22, 2019 Category: Cancer & Oncology Authors: da Cunha LP, Silveira MN, Mendes MCS, Costa FO, Macedo LT, de Siqueira NS, Carvalheira JBC Tags: Clin Nutr ESPEN Source Type: research

Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era.
This article begins with a brief overview of risk factors for colorectal neoplasia in inflammatory bowel disease to concretize the approach to risk stratification. It then provides an up-to-date review of diagnosis and management of dysplasia in inflammatory bowel disease, which integrates new and emerging data in the field. This is particularly relevant in an era of increased attention to cost- and resource-containment from the health systems vantage point, coupled with a heightened prioritization of patient quality of life and shared decision-making. Also provided is a brief discussion of the status of newer therapeutic ...
Source: Clinical Colorectal Cancer - May 14, 2019 Category: Cancer & Oncology Authors: Shah SC, Itzkowitz SH Tags: Gastrointest Endosc Clin N Am Source Type: research

Gut Microbiome in Health and Disease: Emerging Diagnostic Opportunities.
Abstract The gut microbiome is fundamental to human health and development. Altered microbiomes have been associated with many diseases. However, variation between individuals, environmental effects, and a lack of standardization across studies makes differentiation between health and disease challenging. Large-scale population cohorts in different countries will be required to match disease subjects with healthy controls, whereas standardized, reproducible pipelines for analysis are required to compare findings between studies. Despite this, several conditions have already demonstrated great promise for developin...
Source: Clinical Colorectal Cancer - May 4, 2019 Category: Cancer & Oncology Authors: Lavelle A, Hill C Tags: Gastroenterol Clin North Am Source Type: research

Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report.
Abstract The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL...
Source: Clinical Colorectal Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Tokumaru Y, Matsuhashi N, Takahashi T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Yoshida K Tags: Mol Clin Oncol Source Type: research

A randomized placebo-controlled trial of vitamin D supplementation for reduction of mortality and cancer: Statistical analysis plan for the D-Health Trial.
Conclusions: Publication of this statistical analysis plan in advance of the intervention's completion, and adherence to it, will avoid data-driven analyses of the primary and secondary outcomes and ensure robust reporting of outcomes. Clinical trial registration number: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763. Registered on 4 July 2013. PMID: 30886934 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 20, 2019 Category: Cancer & Oncology Authors: Waterhouse M, English DR, Armstrong BK, Baxter C, Duarte Romero B, Ebeling PR, Hartel G, Kimlin MG, McLeod DSA, O'Connell RL, van der Pols JC, Venn AJ, Webb PM, Whiteman DC, Neale RE Tags: Contemp Clin Trials Commun Source Type: research

Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer.
Abstract AIM: To investigate treatment patterns and outcomes of metastatic colorectal cancer (mCRC) patients beyond second progression (PD2) since regorafenib and TAS-102 became available in Hong Kong. METHODS: The clinical records of consecutive mCRC patients who were treated beyond PD2 at Department of Clinical Oncology, Queen Mary Hospital between June 2013 and February 2018, were retrospectively reviewed. RESULTS: Of 176 PD2 patients (76.7% Eastern Cooperative Oncology Group performance status 0/1 and a median follow-up time of 6.6 [range, 0.4-37.2] months), 104 (59%) underwent palliative care only a...
Source: Clinical Colorectal Cancer - March 19, 2019 Category: Cancer & Oncology Authors: Chiang CL, Choi HC, Lam KO, Chan BY, Lee SF, Yeung SY, Lau KS, Chan SY, Choy TS, Yuen KK Tags: Asia Pac J Clin Oncol Source Type: research

The single-base-pair deletion, MSH2 c.2635-3delC affecting intron 15 splicing can be a cause of Lynch syndrome.
Abstract The proband was a 62-year-old man with ureter cancer. He had a history of metachronous colorectal and gastric cancer. Immunohistochemical staining showed the absence of both MSH2 and MSH6 proteins in the ureter cancer and other available cancer tissue specimens. Genetic testing was conducted to identify the causative genes of hereditary gastrointestinal cancer syndromes including mismatch repair genes. We detected a germline variant, c.2635-3delC, within the splice acceptor site of exon 16, in the MSH2 gene. To investigate whether this variant affected splicing of the gene, RNA sequencing was performed us...
Source: Clinical Colorectal Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Ito T, Yamaguchi T, Wakatsuki T, Suzuki T, Eguchi H, Okazaki Y, Yamamoto G, Tachikawa T, Kawakami S, Sasaki A, Akagi K, Ishida H Tags: Jpn J Clin Oncol Source Type: research

The application of ApcMin/+ mouse model in colorectal tumor researches.
CONCLUSION: This article will give a brief review on the related molecular mechanisms of the ApcMin/+ mouse model and its application in colorectal tumor researches. PMID: 30887153 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Ren J, Sui H, Fang F, Li Q, Li B Tags: J Cancer Res Clin Oncol Source Type: research

Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA.
CONCLUSIONS: Results of this study validated the capability of stool DNA based-SDC2 methylation test by LTE-qMSP for early detection of CRC patient with high specificity. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03146520 , Registered 10 May 2017, Retrospectively registered; however, control arm was prospectively registered. PMID: 30876480 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 15, 2019 Category: Cancer & Oncology Authors: Han YD, Oh TJ, Chung TH, Jang HW, Kim YN, An S, Kim NK Tags: Clin Epigenetics Source Type: research

Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
CONCLUSION: The present results provide evidence that tumor PD-L1 expression and recruitment of CD8+ TILs within the tumor microenvironment were increased by neoCRT treatment. Tumor PD-L1 and CD8+ TILs are prognostic biomarkers for the survival of LARC patients treated with neoCRT. PMID: 30874889 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 14, 2019 Category: Cancer & Oncology Authors: Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC Tags: J Cancer Res Clin Oncol Source Type: research

Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study.
This study aimed to evaluate the clinical characteristics and prognosis of primary tumor location (PTL) in colorectal cancer. METHODS: Patients' diagnoses were identified using the Surveillance, Epidemiology, and End Result database between 2006 and 2015. The analyses were further stipulated to patients with primary cancer site, histology, and stage information. The correlations between PTL and overall survival (OS) were assessed. RESULTS: Compared with left-sided tumors, right-sided tumors were more likely to develop into T3 cancers (50.0% vs. 44.8%), T4 cancers (15.8% vs. 12.3%), mucinous or mucin-producing ade...
Source: Clinical Colorectal Cancer - March 14, 2019 Category: Cancer & Oncology Authors: Zheng C, Jiang F, Lin H, Li S Tags: Clin Transl Oncol Source Type: research

Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis.
Conclusion: Our studies revealed that EGFR and HER2 are highly expressed in the primary tumours and metastases of CRC patients with ovarian metastases. HER2 positivity may be a negative prognostic predictor in patients with ovarian metastases. PMID: 30858756 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 13, 2019 Category: Cancer & Oncology Authors: Li JL, Lin SH, Chen HQ, Liang LS, Mo XW, Lai H, Zhang J, Xu J, Gao BQ, Feng Y, Lin Y Tags: BMC Clin Pathol Source Type: research

Study aims to improve colorectal cancer screening rates.
PMID: 30861095 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 12, 2019 Category: Cancer & Oncology Authors: Fillon M Tags: CA Cancer J Clin Source Type: research

Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic.
C, Sears CL Abstract Mucus-invasive bacterial biofilms are identified on the colon mucosa of approximately 50% of colorectal cancer (CRC) patients and approximately 13% of healthy subjects. Here, we test the hypothesis that human colon biofilms comprise microbial communities that are carcinogenic in CRC mouse models. Homogenates of human biofilm-positive colon mucosa were prepared from tumor patients (tumor and paired normal tissues from surgical resections) or biofilm-positive biopsies from healthy individuals undergoing screening colonoscopy; homogenates of biofilm-negative colon biopsies from healthy individua...
Source: Clinical Colorectal Cancer - March 11, 2019 Category: Cancer & Oncology Authors: Tomkovich S, Dejea CM, Winglee K, Drewes JL, Chung L, Housseau F, Pope JL, Gauthier J, Sun X, Mühlbauer M, Liu X, Fathi P, Anders RA, Besharati S, Perez-Chanona E, Yang Y, Ding H, Wu X, Wu S, White JR, Gharaibeh RZ, Fodor AA, Wang H, Pardoll DM, Jobin C, Tags: J Clin Invest Source Type: research

Green tea intake and colorectal cancer risk in Japan: the Takayama study.
CONCLUSIONS: This study observed no overall significant associations between green tea consumption and colorectal cancer risk, except that there was a weak trend for greater consumption of green tea with decreased risk of male colon cancer. PMID: 30855678 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 11, 2019 Category: Cancer & Oncology Authors: Wada K, Oba S, Tsuji M, Goto Y, Mizuta F, Koda S, Uji T, Hori A, Tanabashi S, Matsushita S, Tokimitsu N, Nagata C Tags: Jpn J Clin Oncol Source Type: research

Relationship between computed tomography-derived body composition, sex, and post-operative complications in patients with colorectal cancer.
Abstract INTRODUCTION: In the UK, colorectal cancer is the fourth most common cancer and the second most common cause of cancer death. Surgery is the primary modality of treatment, but it is not without complications. Post-operative complications have been linked to preoperative of weight loss and loss of lean tissue, and also to obesity. Given sex differences in body composition, an examination of body composition and post-operative complications may provide valuable information. Therefore, the aim was to examine the relationship between male/female body composition and post-operative complications in patients wi...
Source: Clinical Colorectal Cancer - March 11, 2019 Category: Cancer & Oncology Authors: Almasaudi AS, Dolan RD, McSorley ST, Horgan PG, Edwards C, McMillan DC Tags: Eur J Clin Nutr Source Type: research

Meeting report of the 14th Japan-Korea joint symposium on cancer and aging research: current status of translational research and approaches to precision medicine.
CONCLUSION: The 14th symposium demonstrated the cutting-edge of presentations with discussion of numerous ideas by the participants. PMID: 30859317 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 11, 2019 Category: Cancer & Oncology Authors: Sueoka E, Watanabe T, Mashima T, Shirakami Y, Komori A, Matsuo K, Yoshikawa HY, Cho KA, Park TJ, Seimiya H, Kim EG, Suganuma M, Chung J Tags: J Cancer Res Clin Oncol Source Type: research

Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation.
CONCLUSION: The current research reveals a vital role of CRIP1 in CRC progression, which provide a novel target for clinical drug resistance of colorectal cancer and undoubtedly contributing to the therapeutic strategies in CRC. PMID: 30850009 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 8, 2019 Category: Cancer & Oncology Authors: Zhang L, Zhou R, Zhang W, Yao X, Li W, Xu L, Sun X, Zhao L Tags: J Exp Clin Cancer Res Source Type: research

Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
Abstract BACKGROUND: Epigenetic alternation is a common contributing factor to neoplastic transformation. Although previous studies have reported a cluster of aberrant promoter methylation changes associated with silencing of tumor suppressor genes, little is known concerning their sequential DNA methylation changes during the carcinogenetic process. The aim of the present study was to address a genome-wide search for identifying potentially important methylated changes and investigate the onset and pattern of methylation changes during the progression of colorectal neoplasia. METHODS: A three-phase design wa...
Source: Clinical Colorectal Cancer - March 7, 2019 Category: Cancer & Oncology Authors: Gu S, Lin S, Ye D, Qian S, Jiang D, Zhang X, Li Q, Yang J, Ying X, Li Z, Tang M, Wang J, Jin M, Chen K Tags: Clin Epigenetics Source Type: research

Iron oxide-gold core-shell nano-theranostic for magnetically targeted photothermal therapy under magnetic resonance imaging guidance.
Abstract Recent efforts in the area of photothermal therapy (PTT) follow two important aims: (i) selective targeting of plasmonic nanoparticles to the tumor and (ii) real-time guidance of PTT operation through employing multimodal imaging modalities. In the present study, we utilized a multifunctional theranostic nanoplatform constructed from iron (III) oxide-gold (Fe2O3@Au) core-shell nanoparticles to fulfill these aims. The Au shell exhibits surface plasmon resonance, a property that is exploited to realize PTT. The magnetic core enables Fe2O3@Au to be employed as a magnetic resonance imaging (MRI) contrast agen...
Source: Clinical Colorectal Cancer - March 7, 2019 Category: Cancer & Oncology Authors: Abed Z, Beik J, Laurent S, Eslahi N, Khani T, Davani ES, Ghaznavi H, Shakeri-Zadeh A Tags: J Cancer Res Clin Oncol Source Type: research

Effect of Imperfect Compliance With Instructions for Fecal Sample Collection on Diagnostic Performance of 9 Fecal Immunochemical Tests.
CONCLUSIONS: Violations of fecal sampling instructions can lead to non-negligible variations in fecal hemoglobin measurements. The limited adverse effects on diagnostic performance indicate the robustness of FITs. The potential for increasing diagnostic performance by collecting more stool material should be followed up in further research. PMID: 30851476 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Gies A, Gruner LF, Schrotz-King P, Brenner H Tags: Clin Gastroenterol Hepatol Source Type: research

Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns.
rhoef C Abstract The majority of patients recur after resection of colorectal liver metastases (CRLM). Patients with CRLM displaying a desmoplastic histopathological growth pattern (dHGP) have a better prognosis and lower probability of recurrence than patients with non-dHGP CRLM. The current study evaluates the impact of HGP type on the pattern and treatment of recurrences after first resection of CRLM. A retrospective cohort study was performed, including patients with known HGP type after complete resection of CRLM. All patients were treated between 2000 and 2015. The HGP was determined on the CRLM resected at ...
Source: Clinical Colorectal Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Nierop PMH, Galjart B, Höppener DJ, van der Stok EP, Coebergh van den Braak RRJ, Vermeulen PB, Grünhagen DJ, Verhoef C Tags: Clin Exp Metastasis Source Type: research

First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.
CONCLUSION: Deflexifol is safer and effective in bolus and infusion schedules at higher doses than that permitted by separate infusion of 5-FU and LV. A phase II study evaluating Deflexifol is planned. PMID: 30843362 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Clingan PR, Ackland SP, Brungs D, de Souza P, Aghmesheh M, Garg MB, Ranson RD, Parker S, Jokela R, Ranson M Tags: Asia Pac J Clin Oncol Source Type: research

Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival.
CONCLUSIONS: CRC survivors are at increased risk for mental health disorders in the short-term and long-term. Survivors who develop mental health disorders also experience decreased survival. PMID: 30844850 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 5, 2019 Category: Cancer & Oncology Authors: Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M Tags: Am J Clin Oncol Source Type: research

FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis.
CONCLUSION: FAT4 can regulate the activity of PI3K to promote autophagy and inhibit the EMT in part through the PI3K/AKT/mTOR and PI3K/AKT/GSK-3β signaling pathways. PMID: 30832706 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 4, 2019 Category: Cancer & Oncology Authors: Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W Tags: J Exp Clin Cancer Res Source Type: research

Contemporary Opportunity for Prehabilitation as Part of an Enhanced Recovery after Surgery Pathway in Colorectal Surgery.
Abstract The implementation of upfront, preoperative habilitation ("prehabilitation"), as opposed to postoperative habilitation (rehabilitation), provides a unique opportunity to optimize surgical outcomes, while ensuring that patients receive necessary conditioning that may otherwise be significantly delayed by postoperative complications. In this review, opportunities to design, implement, monitor, and evaluate a surgical prehabilitation program in colorectal surgery are discussed, and broken down to include emotional, physical, and nutritional aspects of care in the preoperative setting. PMID: 30...
Source: Clinical Colorectal Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Ven Fong Z, Chang DC, Lillemoe KD, Nipp RD, Tanabe KK, Qadan M Tags: Clin Colon Rectal Surg Source Type: research

Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development.
CONCLUSION: Collectively, these results support a role of defective cohesin in the development of human colorectal cancer. PMID: 30823889 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2019 Category: Cancer & Oncology Authors: Sarogni P, Palumbo O, Servadio A, Astigiano S, D'Alessio B, Gatti V, Cukrov D, Baldari S, Pallotta MM, Aretini P, Dell'Orletta F, Soddu S, Carella M, Toietta G, Barbieri O, Fontanini G, Musio A Tags: J Exp Clin Cancer Res Source Type: research

TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/ β-catenin signaling pathway.
CONCLUSIONS: TRIM29 induces EMT through activating the Wnt/β-catenin signaling pathway via up-regulating CD44 expression, thus promoting invasion and metastasis of CRC. PMID: 30813948 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 27, 2019 Category: Cancer & Oncology Authors: Sun J, Zhang T, Cheng M, Hong L, Zhang C, Xie M, Sun P, Fan R, Wang Z, Wang L, Zhong J Tags: J Exp Clin Cancer Res Source Type: research

Impact of hypochloremia in resected colorectal cancer patients.
PMID: 30823846 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 25, 2019 Category: Cancer & Oncology Authors: Tsutsui M, Yamamoto S Tags: Chin Clin Oncol Source Type: research

Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy.
Abstract Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or switching to a different antiangiogenic monoclonal antibody such as aflibercept or ramucirumab. In the selection of treatment, patient-based factors such as performance status, age, tumor burden, and tolerance and sensitivity to the first-line bevacizumab-based therapy, as well as treatment-related factors such as...
Source: Clinical Colorectal Cancer - February 24, 2019 Category: Cancer & Oncology Authors: Kanat O, Ertas H Tags: World J Clin Oncol Source Type: research

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer.
CONCLUSION: The modification of the FOLFIRI regimen impacted treatment response of mCRC patients. The addition of an antiangiogenic agent, in particular aflibercept, enhanced the clinical benefit and improved survival. PMID: 30815374 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 24, 2019 Category: Cancer & Oncology Authors: Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F Tags: World J Clin Oncol Source Type: research

Aspirin, clopidogrel and colorectal cancer: two roads to the same end?
PMID: 30807844 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 23, 2019 Category: Cancer & Oncology Authors: Jovani M, Chan AT Tags: Clin Gastroenterol Hepatol Source Type: research

Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections.
CONCLUSION: Despite high colonoscopy quality, the yield of CRC at surveillance colonoscopy 1 year after CRC resection was 1.7%. These were metachronous CRCs and recurrences, often of advanced stage. The high yield justifies the recommendation of a 1-year surveillance interval after surgical CRC resection. PMID: 30802606 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 22, 2019 Category: Cancer & Oncology Authors: van Lanschot MCJ, van Leerdam ME, Lansdorp-Vogelaar I, Doets S, Nagtegaal ID, Schreurs HW, van der Hulst RWM, Carvalho B, Dekker E, van Berkel AM Tags: Clin Gastroenterol Hepatol Source Type: research

Multiple sclerosis outcomes after cancer immunotherapy.
CONCLUSIONS: Reported MS relapses after ICI are rare, but the adverse events described include rapid neurologic progression and death. Larger and prospective studies are warranted to assess disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients with MS. PMID: 30788836 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL Tags: Clin Transl Oncol Source Type: research

Allium vegetables are associated with reduced risk of colorectal cancer: A hospital-based matched case-control study in China.
Abstract AIM: The present study aimed to investigate and identify the association between the intake of allium vegetables and colorectal cancer (CRC) in population. METHODS: A hospital-based matched case-control study was conducted between June 2009 and November 2011 in three hospitals. Eight hundred thirty three consecutively recruited cases of CRC were frequency matched to 833 controls by age (within 2.5 years of difference), sex, and residence area (rural/urban). Demographic and dietary information were collected via face-to-face interviews using a validated food frequency questionnaire. Adjusted odds rati...
Source: Clinical Colorectal Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Wu X, Shi J, Fang WX, Guo XY, Zhang LY, Liu YP, Li Z Tags: Asia Pac J Clin Oncol Source Type: research

Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response.
RC, Berzofsky JA Abstract It is widely believed that protection against acquisition of HIV or SIV infection requires anti-envelope (anti-Env) antibodies, and that cellular immunity may affect viral loads but not acquisition, except in special cases. Here we provide evidence to the contrary. Mucosal immunization may enhance HIV vaccine efficacy by eliciting protective responses at portals of exposure. Accordingly, we vaccinated macaques mucosally with HIV/SIV peptides, modified vaccinia Ankara-SIV (MVA-SIV), and HIV-gp120-CD4 fusion protein plus adjuvants, which consistently reduced infection risk against heterolog...
Source: Clinical Colorectal Cancer - February 18, 2019 Category: Cancer & Oncology Authors: Sui Y, Lewis GK, Wang Y, Berckmueller K, Frey B, Dzutsev A, Vargas-Inchaustegui D, Mohanram V, Musich T, Shen X, DeVico A, Fouts T, Venzon D, Kirk J, Waters RC, Talton J, Klinman D, Clements J, Tomaras GD, Franchini G, Robert-Guroff M, Trinchieri G, Gallo Tags: J Clin Invest Source Type: research

Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
CONCLUSION: Biweekly SOX regimen with reintroduction of oxaliplatin could be exploitable as the third- and/or later-line treatments for patients with mCRC. PMID: 30778794 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 18, 2019 Category: Cancer & Oncology Authors: Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K, Mishima H Tags: Int J Clin Oncol Source Type: research

Effect of Cotinine-verified Change in Smoking Status on Risk of Metachronous Colorectal Neoplasia After Polypectomy.
CONCLUSION: In a retrospective study of individuals with at least one adenoma, we found that cotinine-verified changes in smoking status between index and follow-up colonoscopy are associated with risk of metachronous CRN. Helping patients quit smoking is important to effective prevention of colorectal cancer. PMID: 30772586 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 14, 2019 Category: Cancer & Oncology Authors: Jung YS, Kim NH, Lee MY, Park JH, Park DI, Sohn CI Tags: Clin Gastroenterol Hepatol Source Type: research

Recommendations for follow-up of colorectal cancer survivors.
Cebrián JM Abstract Colorectal cancer (CRC) is one of the tumours with the highest incidence and mortality in the Spanish population. Nevertheless, the advances in prevention and treatment have contributed to an increased number of patients who survive for prolonged periods of time. In addition, despite recurrences, improved survival following metastasis resection is likewise on the rise. This underscores the importance of carrying out follow-up programmes even in low-risk patients for the early detection of recurrence. The main objective of this article is to provide a set of recommendations for optimising...
Source: Clinical Colorectal Cancer - February 14, 2019 Category: Cancer & Oncology Authors: Vera R, Aparicio J, Carballo F, Esteva M, González-Flores E, Santianes J, Santolaya F, Fernández-Cebrián JM Tags: Clin Transl Oncol Source Type: research

Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.
Abstract BACKGROUND: Metastatic colorectal cancer (mCRC) patients with a right-sided primary (RC) have an inferior survival to mCRC arising from a left-sided primary (LC). Previous analyses have suggested multiple factors contribute. METHODS: The Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Registry prospectively captured data on consecutive mCRC patients. RC were defined as tumors proximal to the splenic flexure; LC were those at and distal to the splenic flexure and included rectal cancers. Patient, tumor, treatment, and survival data were analyzed stratified by side. RESULTS: Of ...
Source: Clinical Colorectal Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Mendis S, Beck S, Lee B, Lee M, Wong R, Kosmider S, Shapiro J, Yip D, Steel S, Nott L, Jennens R, Lipton L, Burge M, Field K, Ananda S, Wong HL, Gibbs P Tags: Asia Pac J Clin Oncol Source Type: research

Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence.
In this study, we quantitatively assessed the mRNA expression status of KLK5 in 197 colorectal tissues from 133 patients (70 cancerous and their paired normal colonic mucosa for 64 of them, as well as 63 colorectal adenomas) by quantitative real-time PCR (qPCR) using TaqMan probes. Statistical analysis evaluated the results. Results It was shown that KLK5 expression is reduced following the histologically non-cancerous-adenoma sequence (p
Source: Clinical Colorectal Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Papachristopoulou G, Malachias A, Devetzi M, Kamouza E, Scorilas A, Xynopoulos D, Talieri M Tags: Clin Chem Lab Med Source Type: research

Comparison of N-glycans expressed in tumor tissues with those expressed in adjacent non-tumor tissues of colorectal cancer patients 
.
CONCLUSION: N-glycans presented only in stage I tumor from the biopsy sample for the diagnosis of CRC or in stage I control obtained during the surgery showed potential as biomarkers to predict CRC prognosis. Further high-throughput glycomic study should be performed with a larger sample size.
. PMID: 30738496 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 10, 2019 Category: Cancer & Oncology Authors: Ji E Tags: Int J Clin Pharmacol Ther Source Type: research

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.
Conclusions: Regorafenib in our clinical practice has equal efficacy to reported data from pivotal registration trials. Our data suggest that performance status is the most important prognostic factor in patients treated with regorafenib, suggesting a careful selection of patients. PMID: 30728734 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 9, 2019 Category: Cancer & Oncology Authors: Aljubran A, Elshenawy MA, Kandil M, Zahir MN, Shaheen A, Gad A, Alshaer O, Alzahrani A, Eldali A, Bazarbashi S Tags: Clin Med Insights Oncol Source Type: research

Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False.
Conclusions: There is a probable association between non-alcoholic steatohepatitis (NASH) and irinotecan. Oxaliplatin seems to lead to higher vascular lesions. Except in the presence of pre-existent comorbidities, liver toxicities should not restrain the use of pre-operative chemotherapy prior to parenchymal-sparing surgery. PMID: 30718969 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 7, 2019 Category: Cancer & Oncology Authors: Desjardin M, Bonhomme B, Le Bail B, Evrard S, Brouste V, Desolneux G, Fonck M, Bécouarn Y, Béchade D Tags: Clin Med Insights Oncol Source Type: research

Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation.
Abstract Colorectal cancer (CRC) is common with 3% of cases associated with germline mutations in the mismatch repair pathway characteristic of Lynch syndrome (LS). The UK National Institute for Health and Care Excellence recommends screening for LS in all patients newly diagnosed with CRC, irrespective of age. The Yorkshire Cancer Research Bowel Cancer Improvement Programme includes a regional LS screening service for all new diagnoses of CRC. In the first 829 cases screened, 80 cases showed deficient mismatch repair (dMMR) including four cases showing areas with loss of expression of all four mismatch repair pro...
Source: Clinical Colorectal Cancer - February 5, 2019 Category: Cancer & Oncology Authors: Westwood A, Glover A, Hutchins G, Young C, Brockmoeller S, Robinson R, Worrilow L, Wallace D, Rankeillor K, Adlard J, Quirke P, West N Tags: J Clin Pathol Source Type: research

Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis.
CONCLUSION: ETS is a simple and interesting intermediate endpoint for clinical practice and future trials of medical treatments of patients with mCRC, but a large prospective analysis and validation are mandatory. PMID: 30719690 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 4, 2019 Category: Cancer & Oncology Authors: Colloca GA, Venturino A, Guarneri D Tags: Int J Clin Oncol Source Type: research

Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
Abstract Primary sclerosing cholangitis (PSC) is a chronic and progressive disease of the biliary tract. PSC is strongly associated with inflammatory bowel disease (IBD), mainly with ulcerative colitis, and most PSC patients have underlying IBD. The pathophysiological interactions between IBD and PSC are unclear, although it seems that the patients with IBD and PSC have a distinct phenotype. IBD with coexisting PSC is more extensive and is characterized by milder activity compared to IBD alone. The coexistence of PSC increases the risk for colorectal cancer in IBD patients and lifelong annual surveillance colonosc...
Source: Clinical Colorectal Cancer - February 1, 2019 Category: Cancer & Oncology Authors: Fousekis FS, Theopistos VI, Mitselos IV, Skamnelos A, Kavvadias A, Katsanos KH, Christodoulou DK Tags: J Clin Med Res Source Type: research

RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications.
Abstract The RAS family is among the most commonly mutated genes in all human malignancies including colon cancer. In normal cells, RAS proteins act as a link in the intracellular signal transduction initiated by binding of growth factors to cell membrane receptors mediating cell survival. RAS isoproteins have great morphological similarities, but despite that, they are thought to have different functions in different tissues. RAS mutations, as supported by several studies including animal models, have a role in the development and progression of colorectal cancer. The detection of RAS mutations in patients with c...
Source: Clinical Colorectal Cancer - January 28, 2019 Category: Cancer & Oncology Authors: Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, Cimadamore A, Massari F, Santoni M, Cheng L Tags: J Clin Pathol Source Type: research